Core Viewpoint - Zoetis Inc. is conducting a private offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029, targeting qualified institutional buyers under Rule 144A of the Securities Act of 1933 [1]. Group 1 - The offering consists of convertible senior notes with a maturity date in 2029 [1]. - The interest rate on the notes is set at 0.25% [1]. - The initial purchasers of the notes have been granted an option, although the specifics of this option are not detailed in the provided text [1].

Company Action - Zoetis 寻求通过可转换债券出售筹集 17.5 亿美元 [1]

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) (the "Company†or "Zoetis†) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the "Notes†) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the "Securities Act†). Zoetis also intends to grant the initial purchasers of th ...

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7] Investment Landscape - Wall Street is investing hundreds of billions into AI, but there is a pressing concern regarding the energy supply needed to sustain this growth [2] - AI data centers, such as those powering large language models, consume energy equivalent to that of small cities, indicating a significant strain on global power grids [2] Company Profile - The company in focus is not a chipmaker or cloud platform but is positioned as a vital player in the energy sector, particularly in nuclear energy infrastructure [7] - It is capable of executing large-scale engineering, procurement, and construction (EPC) projects across various energy sectors, including oil, gas, and renewable fuels [7] Financial Position - The company is noted for being completely debt-free and holding a substantial cash reserve, which is nearly one-third of its market capitalization [8] - It is trading at less than 7 times earnings, making it an attractive investment opportunity compared to other firms in the energy and utility sectors [10] Market Trends - The company is poised to benefit from the onshoring trend driven by tariffs, as well as the surge in U.S. LNG exports under the current administration's energy policies [5][14] - There is a growing recognition on Wall Street of this company's potential, as it quietly capitalizes on multiple favorable market trends without the high valuations seen in other sectors [8][6] Future Outlook - The demand for AI is expected to continue rising, leading to an increased need for energy infrastructure, positioning this company as a critical player in the future energy landscape [3][12] - The influx of talent into the AI sector is anticipated to drive rapid advancements, further solidifying the importance of energy supply in supporting these innovations [12][13]

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and ...

物抗感染中心"将依托硕腾深厚的研发与临床积累，以及京东健康的用户触达与数字化服务能力，开展疾病知识、自 检指导、用药规范等相关科普，破解宠物感染防治领域的信息壁垒，为千万宠物主提供权威、便捷、科学的健康解决 方案。用户在京东"宠物抗感染中心"，即可直达该页面。 12月10日，全球领先的动物保健企业硕腾（Zoetis）旗下经典宠物抗生素——速诺®（Synulox®）在京东健康全网独家 首发。京东健康将持续发挥"全球健康新品线上首发平台"的能力优势，与硕腾在正品保障、专业科普、用户教育及全 渠道分发等领域深度协同，推动宠物抗感染用药更规范、更可及。 《2024年中国宠物医疗行业白皮书》数据显示，截至2024年底，我国城镇犬猫数量已突破1.2亿只，宠物主年均医疗支 出同比增长21.3%，处方药增速显著高于非处方药。同时，超68%的宠物主明确表示"更愿意选择具有国际临床验证背 景的原研药品"，对药品的安全性、有效性及来源可追溯性的关注度持续攀升。在此背景下，高品质处方药的规范性 与可及性提升，已成为推动宠物医疗行业高质量发展的关键环节。 硕腾作为全球领先的动物保健企业，拥有逾70年的行业积淀，始终致力于为宠物主、执业 ...

​Zoetis Inc. (NYSE:ZTS) is one of the Good Stocks to Buy According to Analysts. On December 2, Zoetis Inc. (NYSE:ZTS) held its innovation day, highlighting its long-term growth opportunities. In addition, Wall Street maintains a positive outlook on the stock. ​Management noted that the animal health market is anticipated to grow nearly double the current size to $90 billion by 2035. This is pertinent for the company as its pipeline includes 12 candidates with blockbuster potential treating chronic kidney ...

Barclays sets a price target of $136 for Zoetis Inc. (NYSE:ZTS), indicating a potential increase of approximately 15.1%.Zoetis showcases its strategies and innovations at the Piper Sandler 37th Annual Healthcare Conference, emphasizing its leadership in the animal health industry.The company's stock has experienced significant fluctuations, with a high of $181.85 and a low of $115.25 over the past year, maintaining a strong market capitalization of approximately $52.07 billion.Zoetis Inc. (NYSE:ZTS) is a pr ...

Core Insights - Zoetis Inc. has received approval from Health Canada for Portela™ (relfovetmab injection), aimed at alleviating pain associated with osteoarthritis (OA) in cats [1] - Portela is designed to provide three months of OA pain relief with a single injection, targeting anti-nerve growth factor (NGF), a key mediator of OA pain and inflammation [1] - A nine-month field trial conducted in Europe demonstrated Portela's effectiveness in alleviating OA pain and confirmed its safety [1]

Question-and-Answer SessionSo we'll get right into Q&A. You're coming off your R&D Day. One of the things that we did find pretty interesting is your likelihood of approval. Can you remind investors of why your R&D efficiency is so high? And then can you talk about some of the products you're most excited about coming on Innovation Day?Kristin PeckCEO & Director Sure. Well, we were really excited for those who were able to join us for our webcast on Tuesday morning, really focused on R&D, and we talked abou ...